Industry Trends-Drug launches

The emerging pharmaceutical and biotech industry is thriving. Between 2006 and 2015, 105 companies-the majority of which were in the US-launched a product for the first time. And, over 60 percent of those products were originally discovered in universities and small biotech companies.  Read More

Industry Trends-Top 10 pharma R&D budgets in 2016

Last Year, biopharma won its share of new drug approvals,though not as many as we're used to in the U.S.,as research spending came to fruition.But drug makers also suffered a number of R&D setbacks,cut research staff,rejigged their operations and refocused their pipelines.its Drug R&D also found itself in the spotlight as one of the biggest political issues to arise last year-drug pricing-became inextricably linked to the cost of biomedical research and development.U.S. industry groups PhRMA and BIO,as well as Europe's EFPIA and the U.K.'s ABPI,have all said, and will continue to say,that the inherent reason drug prices are what they are is because of the huge R&D investment most (though not all) companies funnel into their scientists and labs  Read More

Industry growth drivers - Why Medications are so expensive ?

Medication costs have been rising rapidly in recent years. And not just due to profit-mongering CEOs raising the price of old drugs, like EpiPens.  Read More


  • European Commission Approves Bristol-Myers Squibb's Opdivo
Bristol-Myers Squibb was awarded European Commission approval of Opdivo (nivolumab) as a monotherapy for the treatment of squamous cell cancer of the head and neck in adults progressing on or after platinum-based therapy.  Read More
  • FDA Gives Nod to Radius Health's Osteoporosis Drug Tymlos
Radius Health has gained FDA approval for Tymlos (abaloparatide) injection for the treatment of postmenopausal women with osteoporosis at high risk for fracture, multiple risk factors for fracture or patients who have failed or are intolerant to other available osteoporosis therapy.   Read More
  • Obstacles to the Adoption of Biosimilars for Chronic Diseases
Biologic agents have an increasingly important role in clinical care, accounting for 22% of new US Food and Drug Administration (FDA) drug approvals from 2010-2015 and comprising 28% of overall prescription drug revenue in 2015.1 Biologics are generally made from living organisms and are larger, more complex molecules than conventional small-molecule drugs.   Read More
  • Pharma companies file 15% of patents in India: Report
Around 15 percent of the total 1.3 lakh patents filed in India from 2013 to 2015 was contributed by the pharmaceutical industry, according to report by Clarivate Analytics   Read More
  • Health expenses pushed India's 63 million in debt, one third below poverty
A top healthcare report prepared by one of the world's most well-known consultants, KPMG, has regretted that currently 60 percent hospitals, 75 percent dispensaries and 80 per cent doctors are "located in urban areas, serving only 28 percent of the country's population".  Read More

Pharma Fact sheet

  • How drug makers face global push-back on high prices  
Pharmaceutical companies are under fire around the world as a wave of new treatments for cancer and other serious conditions reach the market at ever rising prices, and the pressure looks set to increase. Next week the debate on drug pricing - a particularly heated topic in the United States - will move to Amsterdam as the Dutch government hosts a forum for World Health Organization (WHO) member states to promote "fair pricing".Read More
  • Generic Drug Industry Headwinds Lead to Moat Downgrades
The generic drug industry has recently faced a number of challenges thanks to greater-than-expected pricing pressure, unfortunate capital-allocation decisions, increasing financial leverage, and concerns about collusion charges.  Read More

Clinical Research and Venture Capital

  • Life sciences firms see some fundraising success but need massive sums
At Apexian Pharmaceuticals, a young biotech firm that has been working for 10 years on new drugs to treat cancer, the script seems nearly perfect.  Read More

Compliance , Rules , Regulations , Guidelines

  • FDA to Create Digital Health Unit
With ongoing work on guidance related to software as a medical device, and a new dedicated unit to digital health coming to the US Food and Drug Administration's Center for Devices and Radiological Health (CDRH), the agency is slowly but surely dipping its toe into the rapidly advancing field.  Read More
  • Biosimilars Forum Seeks More Clarity in FDA Draft Guidance on Biosimilar Interchangeability
The nonprofit industry group Biosimilars Forum is calling on the US Food and Drug Administration (FDA) to clarify that a demonstration of interchangeability represents a distinct requirement for additional data compared to a demonstration of biosimilarity.   Read More
  • India to restart inspections of API mfg facilities in China with huge rise in imports
In order to ensure only quality active pharmaceutical ingredients (API) are imported from countries like China, Government will be restarting inspections of drug manufacturing facilities in China soon.  Read More

Balance Score Card Meeting and Workshop Conducted at VEEDA CR.

Veeda Clinical Research conducted Balance Score Card (BSC) workshop and meeting last week for its employees.Mr.Binoy Gardi and Mr.Apurva Shah,are strong advocates of the BSC. They believe that having a BSC for the whole organization will enhance Veeda's ability to implement its vision'To strive for excellence in quality to become the partner of choice to all our sponsors and stake holders Accordingly.Veeda started working on BSC almost a year back and prepared the strategy map of Veeda. Both Apurva Shah and Binoy Gardi believe that the implementation of the BSC will allow Veeda to monitior "Quality" in a more effective way. In fact because of the BSC the weightage given for the end of year appraisal for Quality metrics for each individual varies from 30% to 90%.  Read More

Upcoming Conferences and Events

Veeda Clinical Research will be participating in the CPHI CHINA Conference on June 20-22, 2017 Shanghai, China.


Vedant Complex, Beside YMCA club S.G.Highway, Vejalpur,Ahmedabad-380051,Gujarat India

Phone:  +91 79 3001 3000 | Fax:  +91 79 3001 3010 | Email: